Moneycontrol PRO
HomeNewsBusinessBuy Narayana Hrudayalaya; target of Rs 765: ICICI Direct

Buy Narayana Hrudayalaya; target of Rs 765: ICICI Direct

ICICI Direct is bullish on Narayana Hrudayalaya has recommended buy rating on the stock with a target price of Rs 765 in its research report dated February 08, 2021.

February 11, 2022 / 20:35 IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct's research report on Narayana Hrudayalaya

NHL operates a chain of multispecialty, tertiary & primary healthcare facilities that initially focused on cardiac & renal but expanded to cancer, neurology, neurosurgery, orthopaedics & gastroenterology facilities. NHL’s network comprises 22 hospitals (including two managed hospitals), five heart centres, 19 primary care facilities (including clinics and information centres) and a multi-speciality hospital in Cayman Islands) Revenue mix Q3FY22 – India: Rs 771.7 crore; (Bangalore:34%, Southern Peripheral:7%, Kolkata:26%, Eastern Peripheral: 5%, Western: 15%, Northern: 13%); Cayman Islands: US$24.9 million

Outlook

We maintain BUY due to 1) consistency in pick-up for elective surgeries in India, 2) steady performance at Cayman Islands and 3) judicious plan to convert/add margin accretive beds or units at existing hospitals We value Narayana at an SOTP of Rs 765 by valuing matured India & Cayman hospitals at 14x FY24E EV/EBITDA, new hospitals at 2x and other business at 1x FY23E EV/sales.

More Info on Trent

At 15:31 hrs Narayana Hrudayalaya was quoting at Rs 653.65, up Rs 6.20, or 0.96 percent.

It has touched an intraday high of Rs 662.35 and an intraday low of Rs 638.40.

It was trading with volumes of 3,027 shares, compared to its thirty day average of 14,894 shares, a decrease of -79.68 percent.

In the previous trading session, the share closed up 1.01 percent or Rs 6.50 at Rs 647.45.

The share touched its 52-week high Rs 679.15 and 52-week low Rs 380.05 on 07 February, 2022 and 25 March, 2021, respectively.

Currently, it is trading 3.75 percent below its 52-week high and 71.99 percent above its 52-week low.

Market capitalisation stands at Rs 13,358.04 crore.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Feb 11, 2022 08:35 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347